Ethosuximide

Nursing pharmacology study reference (NCLEX-style monograph). Numeric values are standard teaching ranges for study and must be verified against current manufacturer labeling before clinical use. This is educational content, not prescribing guidance.

Ethosuximide (brand name Zarontin) — Anticonvulsant; Succinimide (T-type calcium channel blocker).

Identification

• Therapeutic class: Anticonvulsant.
• Pharmacologic class: Succinimide (T-type calcium channel blocker).

Pharmacology

• Mechanism of action: Blocks T-type calcium channels in the thalamus, specific for absence seizures.
• Onset / peak / duration: Effect over days.
• Half-life / therapeutic level: Half-life 30 to 60 hours; therapeutic level 40 to 100 mcg/mL.

Clinical use

• Indications: Absence (petit mal) seizures.
• Usual dose, route, frequency: PO daily or divided; liquid available.
• Maximum dose / adjustments: Titrate to level.

Safety

• Contraindications: Hypersensitivity to succinimides.
• Black box warning: None.
• Interactions: Other antiepileptics, CNS depressants.
• Pregnancy / lactation: Use only if essential.
• High-alert: No.

Adverse effects

• Common side effects: GI upset, drowsiness, hiccups.
• Serious effects to report: Blood dyscrasias, severe rash, behavioral changes.
• Antidote / reversal: None.

Nursing process

• Assessment before administration: CBC, seizure baseline.
• Interventions during therapy: Monitor for infection and bruising.
• Monitor: Drug level, CBC, seizure frequency.
• Evaluation / expected outcome: Absence seizure control.

Patient teaching

• Patient teaching: Report sore throat, fever, or bruising; take with food for GI upset.
• Notify provider if: Fever, sore throat, bruising, rash.
• Administration tips: With food.